- IN8bio Inc INAB provided a clinical update from the ongoing Phase 1 trial of INB-100, an allogeneic or donor-derived, gamma-delta T cell therapeutic candidate in development for patients with high-risk leukemias undergoing haploidentical hematopoietic stem cell transplant (HSCT).
- "We are excited about the early signals of long-term durable responses from gamma-delta T cell therapy in these high-risk AML patients with complex cytogenetics," said Trishna Goswami, Chief Medical Officer of IN8bio.
- "Despite the up to 51% anticipated one-year relapse rate of the patients enrolled in the trial, all three remain alive and disease free for more than one-year post-transplant."
- The Phase 1 trial continues to show positive clinical trends, with the first three patients remaining alive and progression-free.
- Despite multiple cytogenetic abnormalities and a high risk of relapse, these patients remain in remission 26.5, 24.2, and 12.5 months post-transplant, respectively.
- Immune system reconstitution at six months post-treatment demonstrates continued normal function, including observed elevations in T cells, B cells, and gamma-delta T cells.
- No treatment-emergent serious adverse events (SAEs) have been observed.
- The clinical trial is ongoing and additional patients have been recruited, with updated data expected in late 2022.
- Price Action: INAB shares are up 20.04% at $2.65 during the market session on the last check Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.